Inspection Record

Janssen Inc — Health Canada Inspection Findings

Health CanadaInspected 2021-04-27 5 findingsLaboratory and QC controlsDeviation, CAPA, and investigationEquipment and facilityOther quality system

View the regulator's official source The source document is always the basis for judgement.

Findings

1Laboratory and QC controls

The quality control department did not undertake all of the required activities.

2Deviation, CAPA, and investigation

Investigations into deviations, reports, and/or follow-up actions were inadequate.

3Equipment and facility

The availability, content and/or maintenance of the quality agreements between the supplier, fabricator, tester, packager, labeller, distributor, importer, and/or wholesaler was inadequate.

4Other quality system

The recorded information or details were inadequate.

5Other quality system

The assessment, documentation, and/or procedures for considering the resale of returned drugs were inadequate.

About this record

Extracted automatically from the document of the Health Canada inspection on 2021-04-27. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Janssen Inc company profile — full history Health Canada documents, 2021 Go to Findings search